Skip to Content

Health Highlights: Oct. 30, 2017

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

Opioid Company Founder Charged Over Alleged Conspiracy

The founder of a U.S. opioid medication manufacturer was charged Thursday with fraud and racketeering.

John Kapoor of Insys Therapeutics was charged on the same day that President Donald Trump declared the opioid epidemic a national public health emergency, the Associated Press reported.

Thousands of Americans die each year from opioid overdoses.

"In the midst of a nationwide opioid epidemic that has reached crisis proportions, Mr. Kapoor and his company stand accused of bribing doctors to overprescribe a potent opioid and committing fraud on insurance companies solely for profit," said Acting U.S. Attorney William Weinreb in Boston, the AP reported.

"Today's arrest and charges reflect our ongoing efforts to attack the opioid crisis from all angles," he added.

The former CEO of Insys and other executives and managers also face charges. It's alleged that they and Kapoor offered bribes to doctors to write prescriptions for the company's fenantyl-based pain medication meant only for cancer patient with severe pain. Many of the patients who received prescriptions did not have cancer, the AP reported.

© 2020 HealthDay. All rights reserved.

Posted: October 2017

Read this next

1 in 3 High School Seniors Who Misuse Prescription Opioids Turn to Heroin

TUESDAY, Oct. 27, 2020 -- Among high school seniors, nearly a third of those who misuse prescription opioids use heroin by age 35, a new study shows. "It is a very timely study...

Signs America's Opioid Epidemic Might Finally Be Waning

SATURDAY, Oct. 3, 2020 -- Here's some heartening news on the opioid painkillers front: Abuse of the prescription medicines in the United States fell by more than one-quarter...

Was FDA Lax in Approving Opioids Too Easily?

WEDNESDAY, Sept. 30, 2020 -- For at least two decades, the U.S. Food and Drug Administration has been approving new formulations of prescription opioids without requiring drug...